Abstract
AbstractBreast cancer remains the most common cancer in women worldwide. Neoadjuvant chemotherapy (NACT) is often preferred to adjuvant chemotherapy to achieve tumour shrinkage, monitor response to therapy and facilitate surgical removal in the absence of metastases. In addition, there is strong evidence that pathological complete remission (pCR) is associated with prolonged survival. In this study, we sought to identify candidate markers that signal response or resistance to therapy. We present a retrospective longitudinal serum proteomic study of 22 breast cancer patients (11 with pCR and 11 with non-pCR) matched with 21 healthy controls. Serum was analysed by LC-MS/MS after depletion of abundant proteins by immunoaffinity, trypsinisation, isobaric labelling and fractionation by reversed-phase HPLC. We observed an inverse behaviour of the serum proteins c-Met and N-cadherin after the second cycle of chemotherapy with a high predictive value (AUC 0.93). More pronounced changes were observed after the 6th cycle of NACT, with significant changes in the intensity of the proteins contactin-1, centrosomal protein, sex hormone-binding globuline and cholinesterase. Our study highlights the possibility of monitoring response to NACT using serum as a liquid biopsy.
Publisher
Cold Spring Harbor Laboratory
Reference39 articles.
1. Krebs in Deutschland für 2017/2018. 13. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg). Berlin, 2021.
2. Breast cancer statistics | World Cancer Research Fund International [Internet]. WCRF International. [zitiert 27. April 2022]. Verfügbar unter: https://www.wcrf.org/cancer-trends/breast-cancer-statistics/
3. Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage;Breast Cancer Res Treat. Oktober,2014
4. Clinicopathological classification and traditional prognostic indicators of breast cancer;Int J Clin Exp Pathol,2015
5. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design;Clin Breast Cancer. Februar,2009